Between October 18–21, this website will move to a new web address (from health.gov to odphp.health.gov). During that time, some functions might not work as expected. We appreciate your patience and understanding as we’re working to make this transition as smooth as possible.

U.S. Department of Health and Human Services Office of Disease Prevention and Health Promotion

Anti-Vascular Endothelial Growth Factor for Neovascular Age-Related Macular Degeneration

About this resource:

Systematic Review

Source: The Cochrane Collaborative

Last Reviewed: March 2019

Workgroups: Vision Workgroup

In this Cochrane systematic review, the Cochrane Collaborative found that anti‐vascular endothelial growth factor (anti‐VEGF) medicines — pegaptanib, ranibizumab and bevacizumab — improve vision and reduce vision loss in people with neovascular age‐related macular degeneration (wet AMD). People treated with anti-VEGF medicines also had improvements in eye structure. In addition, researchers found that participants who took ranibizumab or bevacizumab for at least 1 year had similar vision outcomes. The main difference between treatments was cost (bevacizumab was cheaper), and very few serious side effects occurred. 

Read more about this resource

Objectives related to this resource (1)

Reduce vision loss from age-related macular degeneration — V‑07
Baseline only

Suggested Citation

1.

Solomon, S. D., Lindsley, K., Vedula, S. S., Krzystolik, M. G., & Hawkins, B. S. (2014). Anti-vascular endothelial growth factor for neovascular age-related macular degeneration. Cochrane Database of Systematic Reviews, 2014 (8). DOI: 10.1002/14651858.CD005139.pub4.